JPWO2020035623A5 - - Google Patents

Claims (17)

A composition comprising a bacterial strain of the species Bifidobacterium breve for stimulating the immune system of a subject. 2. The composition of claim 1, wherein said composition is for treatment of immunodeficiency in a subject. 3. The composition of claim 2, wherein said immunodeficiency is primary or secondary immunodeficiency. (a) the primary immunodeficiency is from X-linked agammaglobulinemia (XLA), chronic granulomatosis (CGD), unclassifiable immunodeficiency (CVID), and severe combined immunodeficiency (SCID) is selected , or
(b) said secondary immunodeficiency is selected from AIDS, cancers of the immune system such as leukemia, viral hepatitis, immune complex diseases such as multiple myeloma;
4. The composition of claim 3. the composition comprising:
a) for use as a vaccine adjuvant,
b) for the treatment, prevention or delay of immunosenescence, or
c) for enhancing cell therapies such as CAR-T,
A composition according to claim 1 . the composition comprising:
a) for use in increasing the expression level and/or activity of IL-12p70, IL-12p70, IFNγ, IL-4, TNF-α and/or IL-17α and/or
b) is for stimulating TLR2 and/or
c) is for stimulating NFκB,
A composition according to any one of claims 1-5 . the bacterial strain is
a) contains a complete exopolysaccharide locus and/or
b) expressing pullulanase,
A composition according to any one of claims 1-6 . A composition comprising a bacterial strain of the species Bifidobacterium breve for the treatment or prevention of a bacterial infection. 9. The composition of claim 8 , wherein said composition is for the treatment or prevention of gastrointestinal bacterial infections. 10. The composition of claim 8 or claim 9 , wherein said composition is for the treatment or prevention of Gram-negative infections. the bacterial strain is
a) has a 16s rRNA gene sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:1 or is represented by SEQ ID NO:1 have a 16s rRNA gene sequence and/or
b) capable of fermenting raffinose and/or
c) fermenting one or more of α-galactosidase, β-galactosidase, α-glucosidase and β-glucosidase, α-arabinose, mannose and raffinose, such as 2, 3, 4, 5, 6 or all 7 and/or
d) the strain deposited with the NCIMB under accession number 42380;
A composition according to any one of claims 1-10 . a) is for oral administration and/or
b) contains one or more pharmaceutically acceptable excipients or carriers, and/or
c) said bacterial strain is lyophilized,
A composition according to any one of claims 1-11 . A composition comprising a bacterial strain of the species Bifidobacterium breve for treating or preventing a disease or condition associated with reduced immune stimulation. A composition comprising cells of a bacterial strain according to any one of claims 1-12 , wherein said cells express one or more heterologous antigens. A cell of a bacterial strain according to any one of claims 1-12 , said cell expressing one or more heterologous antigens. 16. The composition of claim 14 or the cell of claim 15 , wherein said cells present said one or more heterologous antigens. 17. A composition according to claim 14 or 16 or a cell according to claim 15 or 16 for use as a vaccine.